Quantum BioPharma Ltd. (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended September 30, 2026, highlighting improved liquidity, reduced operating expenses, and progress in its clinical development program. The company's cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, representing combined holdings of $12.22 million, compared with $4.12 million at year-end 2025, excluding restricted digital assets. Shareholders' equity increased 91% to $9.77 million, and working capital rose to $5.47 million from $420,000. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million.
Following quarter-end, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. The agreement follows U.S. Food and Drug Administration clearance of the company's Investigational New Drug application in August 2026. Quantum also reported a 21% reduction in operating cash use for the first nine months of 2026 and a decrease in notes payable to $300,000 following repayment of $1 million in debt. Management stated that its cash and digital asset holdings are sufficient to support planned operations over the next 12 months. To view the full press release, visit https://ibn.fm/GJ1ER.
The financial improvements and the advancement of the Lucid-MS trial are significant for Quantum BioPharma and its stakeholders. The company's lead compound, Lucid-MS, is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. With the Phase 2 trial now moving forward, Quantum is taking a critical step toward developing a potential treatment for progressive multiple sclerosis, a condition with limited therapeutic options. The trial's progress could have implications for the broader biopharmaceutical industry, particularly in the field of neurodegenerative disorders.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on the research and development of Lucid-MS. Additionally, Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd and is entitled to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
For more information about Quantum BioPharma, visit Quantum BioPharma (NASDAQ: QNTM). The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.

